// App-Quantinova.ai

EP1078 : NAVITOCLAX AND RUXOLITINIB FOR PATIENTS WITH MYELOFIBROSIS AND JAK INHIBITOR EXPERIENCE: RESPONSE DURATION IN PHASE 2 STUDY

Researchers

Presenter

  • Claire Harrison

Principal Investigators

  • Tim Somervaille

  • James M. Foran

  • Srdan Verstovsek

  • Catriona Jamieson

  • Ruben Mesa

  • Ellen K. Ritchie

  • Srinivas K. Tantravahi

  • Pankit Vachhani

  • Casey L. O'Connell

  • Rami S. Komrokji

  • Pankit Vacchani

  • Jason Harb

  • Jessica E. Hutti

  • Leanne Holes

  • Abdullah A. Masud

  • Jalaja Potluri

  • Naveen Pemmaraju

Medical Centers

  • Division of Hematology and Oncology,Weill Cornell Medical College,New York, NY,United States

  • Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

  • AbbVie Inc., North Chicago, Illinois, United States

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • University of Southern California Keck School of Medicine, Los Angeles, CA

  • Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.

  • Moffitt Cancer Center, Tampa, Florida, United States

  • The Christie NHS Foundation Trust, UK

  • University of Texas San Antonio, San Antonio, Texas, United States

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • Mayo Clinic, Jacksonville, Jacksonville, Florida, United States

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Myelofibrosis

  • Anemia

Biomarkers

  • Janus kinase

Drug/Treatment

  • Ruxolitinib phosphate

  • Navitoclax

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • II

Study Id's

  • NCT03222609

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved